Background: Obesity and metabolic disorders as type 2 diabetes (T2D), nonalcoholic fatty liver disease (NAFLD) or better called metabolic dysfunction fatty liver disease (MAFLD), arterial hypertension (AHT), and obstructive sleep apnea syndrome (OSAS) show a rising prevalence. The increased cardiovascular risk is one of the main causes for death of obese, metabolic ill patients. Sustainable and efficient therapeutic options are needed. Summary: Metabolic surgery not only permits a substantial and lasting weight loss but also ameliorates metabolic co-morbidities and reduces cardiovascular risk and mortality of obese patients. Most existing data focused on T2D, but evidence for other metabolic co-morbidities such as NAFLD, AHT, and OSAS increase constantly. After metabolic surgery, glycemic control of diabetic patients is superior compared to conservative treatment. Also, diabetes related micro- and macrovascular complications are reduced after surgery, and the median life expectancy is over 9 years longer. In patients with MAFLD, metabolic surgery leads to reduction of steatosis and fibrosis while the risk to develop a hepatocellular carcinoma is reduced significantly. Patients with OSAS have an improved lung function and continuous pressure airway treatment during the night is unnecessary in many patients. Patients with AHT need significantly less or even no antihypertensive medication after surgery and the hazard ratio of death is reduced by 49.2%. Therefore, the focus in treating obese and metabolic ill patients is no longer on pure weight loss but on improvement of co-morbidities and reduction of mortality. This is reflected by the updated S3-guidelines of 2018 that provide nationally established consistent guidelines with clear indications for metabolic surgery no longer focusing on body mass index (BMI) only. This article aims to give an overview over the existing literature concerning surgical treatment options for metabolic syndrome. Key Messages: Metabolic co-morbidities impact life-quality and life expectancy of obese patients. Metabolic surgery offers the chance to treat those metabolic co-morbidities independently of the preoperative BMI and should be considered early as a treatment option for obese patients.

1.
Cohen
R
.
Revisional bariatric surgery and choosing the first procedure: twenty-six years of follow-up in the SOS study
.
JAMA Surg
.
2019
;
154
:
326
7
.
2.
Wiggins
T
,
Guidozzi
N
,
Welbourn
R
,
Ahmed
AR
,
Markar
SR
.
Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis
.
PLoS Med
.
2020
;
17
:
e1003206
.
3.
Thereaux
J
,
Lesuffleur
T
,
Czernichow
S
,
Basdevant
A
,
Msika
S
,
Nocca
D
,
.
Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study
.
Lancet Diabetes Endocrinol
.
2019
;
7
:
786
95
.
4.
Roeb
E
,
Steffen
HM
,
Bantel
H
,
Baumann
U
,
Canbay
A
,
Demir
M
,
.
S2k Leitlinie Nicht- alkoholische Fettlebererkrankungen
.
Z Gastroenterol
.
2015
;
53
:
668
723
.
5.
Degasperi
E
,
Colombo
M
.
Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease
.
Lancet Gastroenterol Hepatol
.
2016
;
1
:
156
64
.
6.
Lassailly
G
,
Caiazzo
R
,
Buob
D
,
Pigeyre
M
,
Verkindt
H
,
Labreuche
J
,
.
Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis
.
Gastroenterology
.
2020
;
159
:
1290
301.e5
.
7.
Panunzi
S
,
De Gaetano
A
,
Carnicelli
A
,
Mingrone
G
.
Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis
.
Ann Surg
.
2015
;
261
:
459
67
.
8.
Rubino
F
,
Nathan
DM
,
Eckel
RH
,
Schauer
PR
,
Alberti
KG
,
Zimmet
PZ
,
.
Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations
.
Surg Obes Relat Dis
.
2016
;
12
:
1144
62
.
9.
Aminian
A
,
Zajichek
A
,
Tu
C
,
Wolski
KE
,
Brethauer
SA
,
Schauer
PR
,
.
How much weight loss is required for cardiovascular benefits? Insights from a metabolic surgery matched-cohort study
.
Ann Surg
.
2020
;
272
:
639
45
.
10.
DGAV
.
S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen
. AWMF online.
2018
.
11.
Das
SR
,
Everett
BM
,
Birtcher
K
,
Brown
JM
,
Januzzi
JL
Jr
,
Kalyani
RR
,
.
2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee
.
J Am Coll Cardiol
.
2020
;
76
:
1117
45
.
12.
Sjöström
L
.
Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study
.
Int J Obes
.
2008
;
32
(
Suppl 7
):
S93
7
.
13.
Sjöström
L
.
Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery
.
J Intern Med
.
2013
;
273
:
219
34
.
14.
Mingrone
G
,
Panunzi
S
,
De Gaetano
A
,
Guidone
C
,
Iaconelli
A
,
Capristo
E
,
.
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial
.
Lancet
.
2021
;
397
:
293
304
.
15.
Aminian
A
,
Vidal
J
,
Salminen
P
,
Still
CD
,
Nor Hanipah
Z
,
Sharma
G
,
.
Late relapse of diabetes after bariatric surgery: not rare, but not a failure
.
Diabetes Care
.
2020
;
43
:
534
40
.
16.
Syn
NL
,
Cummins
DE
,
Wang
LZ
,
Lin
DJ
,
Zhao
JJ
,
Loh
M
,
.
Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174772 participants
.
Lancet
.
2021
;
397
:
1830
41
.
17.
Müller-Stich
BP
,
Fischer
L
,
Kenngott
HG
,
Gondan
M
,
Senft
J
,
Clemens
G
,
.
Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization: results of a prospective cohort study (DiaSurg 1 study)
.
Ann Surg
.
2013
;
258
:
760
6
.
18.
Billeter
AT
,
Scheurlen
KM
,
Probst
P
,
Eichel
S
,
Nickel
F
,
Kopf
S
,
.
Meta-analysis of metabolic surgery versus medical treatment for microvascular complications in patients with type 2 diabetes mellitus
.
Br J Surg
.
2018
;
105
:
168
81
.
19.
Aminian
A
,
Zajichek
A
,
Arterburn
DE
,
Wolski
KE
,
Brethauer
SA
,
Schauer
PR
,
.
Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity
.
JAMA
.
2019
;
322
:
1271
82
.
20.
Scheurlen
KM
,
Probst
P
,
Kopf
S
,
Nawroth
PP
,
Billeter
AT
,
Müller-Stich
BP
.
Metabolic surgery improves renal injury independent of weight loss: a meta-analysis
.
Surg Obes Relat Dis
.
2019
;
15
:
1006
20
.
21.
Billeter
AT
,
Kopf
S
,
Zeier
M
,
Scheurlen
K
,
Fischer
L
,
Schulte
TM
,
.
Renal function in type 2 diabetes following gastric bypass
.
Dtsch Arztebl Int
.
2016
;
113
:
827
33
.
22.
Shulman
A
,
Peltonen
M
,
Sjöström
CD
,
Andersson-Assarsson
JC
,
Taube
M
,
Sjöholm
K
,
.
Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study
.
Int J Obes
.
2018
;
42
:
964
73
.
23.
Cohen
RV
,
Pereira
TV
,
Aboud
CM
,
Petry
TBZ
,
Lopes Correa
JL
,
Schiavon
CA
,
.
Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial
.
JAMA Surg
.
2020
;
55
:
e200420
.
24.
Younes
R
,
Bugianesi
E
.
NASH in lean individuals
.
Semin Liver Dis
.
2019 Feb
;
39
:
86
95
.
25.
Fouad
Y
,
Waked
I
,
Bollipo
S
,
Gomaa
A
,
Ajlouni
Y
,
Attia
D
.
What’s in a name? Renaming “NAFLD” to “MAFLD”
.
Liver Int
.
2020
;
40
:
1254
61
.
26.
Piscaglia
F
,
Svegliati-Baroni
G
,
Barchetti
A
,
Pecorelli
A
,
Marinelli
S
,
Tiribelli
C
,
.
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study
.
Hepatology
.
2016
;
63
:
827
38
.
27.
Lee
Y
,
Doumouras
AG
,
Yu
J
,
Brar
K
,
Banfield
L
,
Gmora
S
,
.
Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis
.
Clin Gastroenterol Hepatol
.
2019
;
17
:
1040
60.e11
.
28.
Kwak
M
,
Mehaffey
JH
,
Hawkins
RB
,
Hsu
A
,
Schirmer
B
,
Hallowell
PT
.
Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: a propensity matched analysis
.
Am J Surg
.
2020
;
219
:
504
7
.
29.
Wirth
KM
,
Sheka
AC
,
Kizy
S
,
Irey
R
,
Benner
A
,
Simon
G
,
.
Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis: a retrospective cohort analysis
.
Ann Surg
.
2020
;
272
:
32
9
.
30.
Rustgi
VK
,
Li
Y
,
Gupta
K
,
Minacapelli
CD
,
Bhurwal
A
,
Catalano
C
,
.
Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity
.
Gastroenterology
.
2021
;
161
(
1
):
171
84
.
31.
Alam
S
,
Jahid Hasan
M
,
Khan
MAS
,
Alam
M
,
Hasan
N
.
Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient
.
J Transl Int Med
.
2019
;
7
:
106
14
.
32.
Brock
JM
,
Billeter
A
,
Müller-Stich
BP
,
Herth
F
.
Obesity and the lung: what we know today
.
Respiration
.
2020
;
99
:
1
11
.
33.
Kershaw
EE
,
Flier
JS
.
Adipose tissue as an endocrine organ
.
J Clin Endocrinol Metab
.
2004
;
89
:
2548
56
.
34.
Wang
F
,
Xiong
X
,
Xu
H
,
Huang
H
,
Shi
Y
,
Li
X
,
.
The association between obstructive sleep apnea syndrome and metabolic syndrome: a confirmatory factor analysis
.
Sleep Breath
.
2019
;
23
:
1011
9
.
35.
Santamaria
F
,
Montella
S
,
Greco
L
,
Valerio
G
,
Franzese
A
,
Maniscalco
M
,
.
Obesity duration is associated to pulmonary function impairment in obese subjects
.
Obesity
.
2011
;
19
:
1623
8
.
36.
Kuvat
N
,
Tanriverdi
H
,
Armutcu
F
.
The relationship between obstructive sleep apnea syndrome and obesity: a new perspective on the pathogenesis in terms of organ crosstalk
.
Clin Respir J
.
2020
;
14
:
595
604
.
37.
Alsumali
A
,
Al-Hawag
A
,
Bairdain
S
,
Eguale
T
.
The impact of bariatric surgery on pulmonary function: a meta-analysis
.
Surg Obes Relat Dis
.
2018
;
14
:
225
36
.
38.
Peralta
GP
,
Marcon
A
,
Carsin
AE
,
Abramson
MJ
,
Accordini
S
,
Amaral
AF
,
.
Body mass index and weight change are associated with adult lung function trajectories: the prospective ECRHS study
.
Thorax
.
2020
;
75
:
313
20
.
39.
Peters
U
,
Hernandez
P
,
Dechman
G
,
Ellsmere
J
,
Maksym
G
.
Early detection of changes in lung mechanics with oscillometry following bariatric surgery in severe obesity
.
Appl Physiol Nutr Metab
.
2016
;
41
:
538
47
.
40.
Schauer
PR
,
Bhatt
DL
,
Kirwan
JP
,
Wolski
K
,
Aminian
A
,
Brethauer
SA
,
.
Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes
.
N Engl J Med
.
2017
;
376
:
641
51
.
41.
Ikramuddin
S
,
Korner
J
,
Lee
WJ
,
Thomas
AJ
,
Connett
JE
,
Bantle
JP
,
.
Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pres- sure at 5 years in the Diabetes Surgery Study
.
JAMA
.
2018
;
319
:
266
78
.
42.
Schiavon
CA
,
Bhatt
D
,
Ikeoka
D
,
Santucci
EV
,
Santos
RN
,
Damiani
LP
,
.
Three-year outcomes of bariatric surgery in patients with obesity and hypertension: a randomized clinical trial
.
Ann Intern Med
.
2020
;
173
(
9
):
685
93
.
43.
Aminian
A
,
Brethauer
SA
,
Andalib
A
,
Nowacki
AS
,
Jiminet
A
,
Corcelles
R
,
.
Individualized metabolic surgery score: procedure selection based on diabetes severity
.
Ann Surg
.
2017
;
266
(
4
):
650
7
.
44.
Duarte-Guerra
LS
,
Coêlho
BM
,
Santo
MA
,
Wang
YP
.
Psychiatric disorders among obese patients seeking bariatric surgery: results of structured clinical interviews
.
Obes Surg
.
2015
;
25
:
830
7
.
45.
Peterli
R
,
Wölnerhanssen
BK
,
Peters
T
,
Vetter
D
,
Kröll
D
,
Borbély
Y
,
.
Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial
.
JAMA
.
2018
;
319
:
255
65
.
46.
Salminen
P
,
Helmiö
M
,
Ovaska
J
,
Juuti
A
,
Leivonen
M
,
Peromaa-Haavisto
P
,
.
Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial
.
JAMA
.
2018
;
319
:
241
54
.
47.
Robert
M
,
Espalieu
P
,
Pelascini
E
,
Caiazzo
R
,
Sterkers
A
,
Khamphommala
L
,
.
Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial
.
Lancet
.
2019
;
393
:
1299
309
. Erratum in: Lancet. 2019;393(10178):1298.
You do not currently have access to this content.